ResearcherJohns Hopkins UniversityActive in the last 2 years

Brady A. Campbell

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0792-6928; OpenAlex author ID A5054347226. Sources: OpenAlex.

Their work

Papers: 15 (first author 3, last author 0)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 65

Papers, trials and grants by year

2024: 2 papers · 2025: 10 papers · 2026: 3 papers

Papers 15

Integrated driver gene-based survival prediction in resected pancreatic cancer. First author DOI 10.1093/bjs/znag123 ↗
Informing Decision-making for Transected Margin Reresection in Intraductal Papillary Mucinous Neoplasm-derived Pancreatic Cancer: An International Multicenter … Co-author DOI 10.1097/sla.0000000000006532 ↗
Implications of Neoadjuvant Therapy on Prognostic Factors in Pancreatic Ductal Adenocarcinoma: A Path Towards Personalized Prognostication. Co-author DOI 10.1097/sla.0000000000006660 ↗
Recognizing IPMN-derived pancreatic cancer as a specific entity requiring prospective clinical studies: a call for international collaboration. Co-author DOI 10.1093/jnci/djaf037 ↗
Time-varying impact of established prognostic factors in resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/jnci/djaf196 ↗
Neoadjuvant Chemotherapy for Intraductal Papillary Mucinous Neoplasm-derived Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006687 ↗
Carbohydrate Antigen 19-9 Delta Function for Survival Prediction in Borderline Pancreatic Cancer. A PANC-PALS Consortium International Multicenter Derivation a… Co-author DOI 10.1097/sla.0000000000006735 ↗
The Mutational Status of Driver Genes in Patients With Resected Pancreatic Ductal Adenocarcinoma Is Associated With Pathological Characteristics and Overall Su… Co-author DOI 10.1097/sla.0000000000006794 ↗
The Organ-Specific Prognostic Value of TP53 Mutations in Pancreatic Cancer Patients with Oligometastasis Following Surgical Resection. Co-author DOI 10.1097/sla.0000000000006823 ↗
Defining and Predicting Early Recurrence for Optimal Treatment Strategies for Intraductal Papillary Mucinous Neoplasm-Derived Pancreatic Cancer: An Internation… Co-author DOI 10.1245/s10434-024-16649-z ↗
Association Between Adjuvant Therapy and Survival in Resected Pancreatic Ductal Adenocarcinoma After Different Types and Durations of Neoadjuvant Therapy. First author DOI 10.1245/s10434-025-17439-x ↗
ASO Author Reflections: The Impact of Adjuvant Therapy in the Era of Neoadjuvant Strategies for Pancreatic Cancer. First author DOI 10.1245/s10434-025-17788-7 ↗
Incidence and Outcomes of Intraductal Oncocytic Papillary Neoplasm-Derived Pancreatic Cancer Compared with Tubular and Colloid Intraductal Papillary Mucinous N… Co-author DOI 10.1245/s10434-025-17810-y ↗
An international multi-institutional validation of T1 sub-staging of intraductal papillary mucinous neoplasm-derived pancreatic cancer. Co-author DOI 10.1093/jnci/djae166 ↗
Total versus Partial Pancreatectomy in Patients with Pancreatic Cancer Arising from Multifocal or Diffuse Intraductal Papillary Mucinous Neoplasia - A Multicen… Co-author DOI 10.1097/sla.0000000000006538 ↗

Closest collaborators

The 25 strongest of 65 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.